Research In Brief
This article was originally published in The Rose Sheet
Executive Summary
Researchers link blue-light skin-treatment devices, increasingly being implemented in professional settings and used by consumers at home, to vision problems. Chitosan microparticles show promise as delivery mechanism for green tea extract, the antioxidant benefit of which is typically limited due to poor skin penetration. More research in brief.
You may also be interested in...
FDA Warns Quasar For Lack Of Proper Skin-Care Device Clearance; Firm Cites Mix-Up
An FDA warning letter to Quasar Bio-Tech suggests the marketer of Baby Quasar and Quasar MD lacks correct 510(k) device clearance and is improperly marketing its home-use skin-care device products. Quasar maintains it holds the correct clearances, and that FDA may be confused by its product nomenclature.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.